Specific Aim # 3. Develop an oral dosage form of transgenic recombinant human Factor IX, and evaluate in hemophilia B mice and dog models. Oral administration of coagulation therapy will obviate the invasiveness, discomfort, potential for opportunistic infection, and complications of storage and supplies that accompany intravenous administration. Oral dosage forms of Factor IX will thus greatly increase the proportion of the patient population that can be treated. There is also published evidence suggesting that oral administration may reduce the potential for complicating immune responses to replacement therapy, especially in patients with severe hemophilia.
>And we're talking ORAL replacement therapy not just IV<
I wouldn’t bank on that happening in the next decade or so. Even with transgenic production, I doubt that the oral bioavailability of clotting factors will be high enough to make oral administration a practical option. After all, the point of FoB’s is to lower drug costs, not raise them.
News 
Market Data 
Discover 
AI
